DELAVIRDINE

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N6O3S
Molecular Weight	456.563
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)Nc1cccnc1N2CCN(CC2)C(=O)c3cc4cc(ccc4[nH]3)NS(=O)(=O)C

InChI

InChIKey=WHBIGIKBNXZKFE-UHFFFAOYSA-N

InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C22H28N6O3S
Molecular Weight	456.563
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf | https://www.drugs.com/ppa/delavirdine.html

Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. .

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 45 Target ID: CHEMBL247 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/26162497 \| https://www.ncbi.nlm.nih.gov/pubmed/10514285	Inhibitor 7701	HIV-1 infection	21 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 140 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Primary	Human immunodeficiency virus type 1 reverse transcriptase	Approved 7997	RESCRIPTOR Approved Use RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing antiretroviral regimens containing RESCRIPTOR with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the regimen containing RESCRIPTOR who achieved and sustained an HIV-1 RNA level <400 copies/mL over 1 year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES). Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents. Launch Date 860112000000

C_max

Value	Dose	Analyte	Population
2.18 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.23 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
35 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
18.8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
180 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	N-DESISOPROPYL DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9164415/	400 mg 3 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAVIRDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	Disc. AE: Rash, Oral lesion... Other AEs: Fever, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Rash (grade 3-4, 36%) Oral lesion (1 patient) Function liver abnormal (2 patients) Headache (grade 4, 1 patient) Other AEs: Fever (grade 3, 1 patient) Thrombocytopenia (1 patient) Nausea (1 patient) Fatigue (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

AEs

AE	Significance	Dose	Population
Fatigue	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Nausea	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Thrombocytopenia	1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Oral lesion	1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Function liver abnormal	2 patients Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Fever	grade 3, 1 patient	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	grade 3-4, 36% Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Headache	grade 4, 1 patient Disc. AE	400 mg 3 times / day steady, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10348755	unhealthy, >18 years Health Status: unhealthy Age Group: >18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10348755
Rash	3.2% Disc. AE	400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1318	substrate 1038 inhibitor 1421

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 175 CYP2C19 1215 P-gp 1089 MRP1 69 MRP2 341 MRP3 148 CYP1A2 1268	CYP3A 154 P-gp 1223	P-gp 225

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11225565/	negligible
MRP1 129	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP2 421	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
MRP3 200	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/17172311/	yes [Inhibition 16.7 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3	yes [Ki 12.8 uM]
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3	yes [Ki 2.6 uM]
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/11124228/ Page: 3	yes [Ki 24 uM]
CYP3A 244	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3	yes [Ki 9.5 uM]	yes (co-administration study) Comment: coadministration of amprenavir with delavirdine resulted in an approximately 4-fold increase in amprenavir AUC to infinity (AUC∞) and a 6-fold increase in amprenavir Cmin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3;https://pubmed.ncbi.nlm.nih.gov/15544435/ Page: 3
P-gp 1255	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/12180537/	yes
P-gp 1255	inhibitor 2614 Sources: https://aac.asm.org/content/48/4/1073	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2D6 1038	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3	likely
P-gp 1223	substrate 2752 Sources: https://aac.asm.org/content/48/4/1073	no
CYP3A 154	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3	yes	yes (co-administration study) Comment: Coadministration of RESCRIPTOR and drugs that induce CYP3A, such as rifampin, may decrease delavirdine plasma concentrations and reduce its therapeutic effect. With rifampin: 97% decrease in AUC Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf#page=3 Page: 3

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:119573	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119573
MolPort	MolPort-003-846-188	https://www.molport.com/shop/molecule-link/MolPort-003-846-188
ZINC	ZINC000018516586	http://zinc15.docking.org/substances/ZINC000018516586

PubMed

Title	Date	PubMed

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.	1999 Aug 20	10465070
Synthesis and structure-activity relationships of the (alkylamino)piperidine-containing BHAP class of non-nucleoside reverse transcriptase inhibitors: effect of 3-alkylpyridine ring substitution.	1999 Oct 7	10514284
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.	2000 Aug	10898683
Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.	2000 Jan 17	10673109
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.	2000 May	10779379
Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity.	2000 Sep	11142631
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.	2001	11735608
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.	2001	11402860
Saquinavir soft gelatin capsule: a comparative safety review.	2001	11347724
Delavirdine: clinical pharmacokinetics and drug interactions.	2001	11327199
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.	2001 Apr	11264389
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.	2001 Apr 15	11391173
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.	2001 Aug	11477320
Antiviral drugs: current state of the art.	2001 Aug	11418355
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.	2001 Jan	11225565
Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.	2001 Jan	11124228
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.	2001 Jun 15	11416714
Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.	2001 Jun 7	11384232
New developments in anti-HIV chemotherapy.	2001 Nov	11562282
Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.	2001 Nov 15	11679930
Drugs for HIV infection.	2001 Nov 26	11723420
The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.	2001 Nov 30	11572864
Can delavirdine substitute for ritonavir?	2001 Nov-Dec	11794866
HIV-protease inhibitors alter retinoic acid synthesis.	2001 Oct 19	11600826
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.	2001 Sep 3	11527705
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.	2002	11945162
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.	2002 Apr 15	11959068
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.	2002 Dec	12496743
Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	2002 Dec 19	12477355
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.	2002 Jul	12180537
Delavirdine in rescue regimens.	2002 May-Jun	12064317
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.	2002 Nov	12367719
Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.	2002 Sep 6	12218397
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	2003 Dec 15	14643315
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.	2003 Dec 5	14685057
Comparison of nine resistance interpretation systems for HIV-1 genotyping.	2003 Jun	12924541
Protease inhibitor-sparing regimens: new evidence strengthens position.	2003 Jun 1	12946062
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.	2003 Nov 17	14612892
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.	2003 Oct	14640386
Identification and prediction of promiscuous aggregating inhibitors among known drugs.	2003 Oct 9	14521410
Pfizer announces free drug program.	2003 Sep	14596253
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.	2004 Feb	15040537
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.	2004 Feb 26	14971897
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials.	2004 Jan 31	14742351
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	2004 May 6	15115397

Patents

Sample Use Guides

In Vivo Use Guide

HIV-1 infection (part of combination): Oral: 400 mg 3 times/day

Route of Administration: Oral

In Vitro Use Guide

In vitro anti-HIV-1 activity of delavirdine was assessed by infecting cell lines of lymphoblastic and monocytic origin and peripheral blood lymphocytes

Substance Class	Chemical Created by `admin` on `Sat Jun 26 00:55:58 UTC 2021` Edited by `admin` on `Sat Jun 26 00:55:58 UTC 2021`
Record UNII	DOL5F9JD3E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELAVIRDINE

Official Name

English

DELAVIRDINE [VANDF]

Common Name

English

PIPERAZINE, 1-(3-((1-METHYLETHYL)AMINO)-2-PYRIDINYL)-4-((5-((METHYLSULFONYL)AMINO)-1H-INDOL-2-YL)CARBONYL)-

Systematic Name

English

DELAVIRDINE [INN]

Common Name

English

DELAVIRDINE [WHO-DD]

Common Name

English

DELAVIRDINE [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000009948